Continuing cyclin dependent kinase 4/6 inhibition with abemaciclib in metastatic breast cancer patients previously treated with palbociclib or ribociclib: a protocol for systematic review and meta-analysis
Alicia de Luna Aguilar(Hospital Clínico San Carlos), José Á. García-Sáenz(Hospital Clínico San Carlos), Manushak Avagyan(Centre international de recherche sur le cancer), Richa Shah(Centre international de recherche sur le cancer), Javier David Benítez Fuentes(Hospital Clínico San Carlos), Carmen Toledano Rojas(Hospital Clínico San Carlos), Alfonso Lopez de Sa Lorenzo(Hospital Clínico San Carlos), Jorge Bartolomé(Hospital Clínico San Carlos), Fernando Moreno Antón(Hospital Clínico San Carlos), Clara Frick(German Cancer Research Center)
Cited by 0
Related Papers
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
|Annals of Oncology|2011|222
Quantitative estimates of preventable and treatable deaths from 36 cancers worldwide: a population-based study
|The Lancet Global Health|2023|186
The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis
|Nature Cancer|2025|26
Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis
|Breast Cancer Research|2024|19